EMEA undertakes internal reorganisation to improve efficiency
This article was originally published in SRA
The European Medicines Agency, in order to improve its functioning and the way in which it delivers its core tasks, has embarked on a reorganisation plan1.
You may also be interested in...
The Netherlands-based GetReal Institute builds on seven years of multi-stakeholder collaboration to promote greater understanding of real-world evidence.
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
Companies can get the European Medicines Agency’s scientific opinion for their products’ use in EU and non-EU countries at about the same time.